Lista de obras - Paola Queirolo - Dominio Público Uruguay

A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.

artículo científico publicado en 2014

ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion

artículo científico publicado en 2014

Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial

artículo científico publicado en 1999

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

artículo científico publicado en 2018

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

artículo científico publicado en 2015

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

artículo científico publicado en 2016

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

artículo científico publicado en 2010

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

artículo científico publicado en 2017

Biochemotherapy in metastatic melanoma: quo vadis?

artículo científico publicado en 2005

CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.

artículo científico publicado en 2009

CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

artículo científico publicado en 2008

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

artículo científico publicado en 2013

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

artículo científico publicado en 2014

Clinical genetic testing for familial melanoma in Italy: A cooperative study

article

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

artículo científico

Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

artículo científico publicado en 2011

Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function

artículo científico publicado en 2016

Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.

artículo científico publicado en 2013

Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients

artículo científico publicado en 2004

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

artículo científico publicado en 2010

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

artículo científico publicado en 2011

Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent.

artículo científico publicado en 2013

Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy.

artículo científico

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

scholarly article published in Cancer Immunology, Immunotherapy

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.

artículo científico publicado en 1996

INK4/ARF germline alterations in pancreatic cancer patients.

artículo científico publicado en 2004

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

article

Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma

article

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study

artículo científico publicado en 2012

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

artículo científico publicado en 2013

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

artículo científico publicado en 2012

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

artículo científico publicado en 2011

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

artículo científico publicado en 2014

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

scientific article published on 01 December 2020

MC1Rvariation and melanoma risk in relation to host/clinical and environmental factors inCDKN2Apositive and negative melanoma patients

article

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression

artículo científico publicado en 2012

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.

artículo científico publicado en 2012

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

artículo científico publicado en 2006

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

artículo científico publicado en 2016

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer

artículo científico publicado en 2012

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

artículo científico publicado en 2017

Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

artículo científico publicado en 1997

Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma

artículo científico publicado en 2015

Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma.

artículo científico publicado en 2009

Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.

artículo científico publicado en 2012

Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

artículo científico publicado en 2014

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.

artículo científico publicado en 2004

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

artículo científico publicado en 2014

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.

artículo científico publicado en 2010

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.

artículo científico publicado en 2009

Sun exposure and melanoma prognostic factors

artículo científico publicado en 2016

Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.

artículo científico publicado en 2016

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells

artículo científico publicado en 2009

Targeted therapies in melanoma.

artículo científico publicado en 2006

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

artículo científico publicado en 2013

The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma

artículo científico publicado en 2015

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.

artículo científico publicado en 2008

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

artículo científico publicado en 2013

The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group

artículo científico publicado en 2005

The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.

artículo científico publicado en 2014

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

artículo científico publicado en 2014

Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy

artículo científico publicado en 2001

Treatment of metastatic uveal melanoma with intravenous fotemustine

artículo científico publicado en 2013

Upcoming strategies for the treatment of metastatic melanoma.

artículo científico

Update on Metastatic Uveal Melanoma: Progress and Challenges.

artículo científico publicado en 2016

Update: current management issues in malignant melanoma.

artículo científico publicado en 2005

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

artículo científico publicado en 2002

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

artículo científico publicado en 2015

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

artículo científico publicado en 2014

Lista de obras de Paola Queirolo

A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: potential applications in autoimmunity and cancer.

ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion

Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Biochemotherapy in metastatic melanoma: quo vadis?

CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.

CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Clinical genetic testing for familial melanoma in Italy: A cooperative study

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function

Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.

Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent.

Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy.

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.

INK4/ARF germline alterations in pancreatic cancer patients.

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma

Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma

MC1Rvariation and melanoma risk in relation to host/clinical and environmental factors inCDKN2Apositive and negative melanoma patients

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma

Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma.

Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history.

Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.

Sun exposure and melanoma prognostic factors

Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells

Targeted therapies in melanoma.

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

The CDKN2A/p16(INK) (4a) 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group

The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival.

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy

Treatment of metastatic uveal melanoma with intravenous fotemustine

Upcoming strategies for the treatment of metastatic melanoma.

Update on Metastatic Uveal Melanoma: Progress and Challenges.

Update: current management issues in malignant melanoma.

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.